AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 75 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2018. The put-call ratio across all filers is 1.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $1,561,000 | +32.6% | 233,612 | 0.0% | 0.06% | +25.0% |
Q3 2020 | $1,177,000 | -37.7% | 233,612 | 0.0% | 0.04% | -38.9% |
Q2 2020 | $1,888,000 | -58.0% | 233,612 | -58.7% | 0.07% | -64.5% |
Q1 2020 | $4,495,000 | -26.9% | 566,066 | -30.5% | 0.20% | -12.9% |
Q4 2019 | $6,150,000 | +81.5% | 814,588 | 0.0% | 0.23% | +57.4% |
Q3 2019 | $3,389,000 | +44.0% | 814,588 | 0.0% | 0.15% | +54.2% |
Q2 2019 | $2,354,000 | +100.7% | 814,588 | 0.0% | 0.10% | +100.0% |
Q1 2019 | $1,173,000 | -44.2% | 814,588 | 0.0% | 0.05% | -46.7% |
Q4 2018 | $2,102,000 | -41.2% | 814,588 | 0.0% | 0.09% | -30.8% |
Q3 2018 | $3,576,000 | -28.4% | 814,588 | 0.0% | 0.13% | -31.2% |
Q2 2018 | $4,993,000 | -15.9% | 814,588 | 0.0% | 0.19% | -18.2% |
Q1 2018 | $5,938,000 | +16.0% | 814,588 | +30.5% | 0.23% | +17.3% |
Q4 2017 | $5,119,000 | -21.9% | 624,288 | 0.0% | 0.20% | -15.8% |
Q3 2017 | $6,555,000 | -4.8% | 624,288 | 0.0% | 0.23% | -8.2% |
Q2 2017 | $6,886,000 | +14.0% | 624,288 | 0.0% | 0.26% | +9.0% |
Q1 2017 | $6,043,000 | – | 624,288 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |